Role of growth hormone-releasing hormone in dyslipidemia associated with experimental type 1 diabetes

Proceedings of the National Academy of Sciences of the United States of America
Maritza J RomeroAndrew V Schally

Abstract

Dyslipidemia associated with triglyceride-rich lipoproteins (TRLs) represents an important residual risk factor for cardiovascular and chronic kidney disease in patients with type 1 diabetes (T1D). Levels of growth hormone (GH) are elevated in T1D, which aggravates both hyperglycemia and dyslipidemia. The hypothalamic growth hormone-releasing hormone (GHRH) regulates the release of GH by the pituitary but also exerts separate actions on peripheral GHRH receptors, the functional role of which remains elusive in T1D. In a rat model of streptozotocin (STZ)-induced T1D, GHRH receptor expression was found to be up-regulated in the distal small intestine, a tissue involved in chylomicron synthesis. Treatment of T1D rats with a GHRH antagonist, MIA-602, at a dose that did not affect plasma GH levels, significantly reduced TRL, as well as markers of renal injury, and improved endothelial-dependent vasorelaxation. Glucagon-like peptide 1 (GLP-1) reduces hyperglucagonemia and postprandial TRL, the latter in part through a decreased synthesis of apolipoprotein B-48 (ApoB-48) by intestinal cells. Although plasma GLP-1 levels were elevated in diabetic animals, this was accompanied by increased rather than reduced glucagon levels, suggesting...Continue Reading

References

May 15, 1990·The Biochemical Journal·G F Gibbons
Mar 29, 1984·The New England Journal of Medicine·M PressR S Sherwin
Jun 1, 1997·Current Opinion in Lipidology·G F Lewis
Dec 8, 2004·The Journal of Clinical Endocrinology and Metabolism·M Castro CabezasD W Erkelens
Jan 18, 2008·The New England Journal of Medicine·Ronald B GoldbergDaniel J Drucker
Feb 19, 2008·Journal of the American College of Cardiology·Michael MillerUNKNOWN PROVE IT-TIMI 22 Investigators
Dec 19, 2009·Arteriosclerosis, Thrombosis, and Vascular Biology·Richard J Havel
Oct 13, 2010·Proceedings of the National Academy of Sciences of the United States of America·Nikolina DioufaHippokratis Kiaris
Oct 1, 2011·International Journal of Vascular Medicine·Boudewijn KlopManuel Castro Cabezas
Feb 1, 2012·Nature Reviews. Cardiology·Jacob SivertsenTina Vilsbøll
Feb 7, 2012·Proceedings of the National Academy of Sciences of the United States of America·Rudolf LucasAndrew V Schally
Jan 15, 2013·Frontiers in Physiology·Qinghua WangSusanne Wang
Jun 19, 2013·Progress in Lipid Research·Kathleen M Botham, Caroline P D Wheeler-Jones
Jan 11, 2014·Arteriosclerosis, Thrombosis, and Vascular Biology·Alain VeilleuxEmile Levy
Feb 19, 2014·Atherosclerosis·Changting XiaoGary F Lewis
Apr 25, 2014·Diabetes·Yi-Guang ChenMartin J Hessner
Sep 25, 2014·Diabetes Care·Katherine R TuttleMark E Molitch
Jan 3, 2015·The American Journal of Cardiology·Anton P van de WoestijneFrank L J Visseren
Jan 8, 2015·Proceedings of the National Academy of Sciences of the United States of America·Daniel F VatnerGerald I Shulman
Feb 14, 2015·Arteriosclerosis, Thrombosis, and Vascular Biology·Sarah FarrKhosrow Adeli
Apr 30, 2015·Diabetes & Metabolism Journal·Chang Ho Ahn, Sung Hee Choi
Sep 16, 2015·Current Diabetes Reports·Giovanna Beauchamp, Michael J Haller
Oct 18, 2015·Proceedings of the National Academy of Sciences of the United States of America·Xianyang ZhangAndrew V Schally

❮ Previous
Next ❯

Citations

Oct 26, 2016·Frontiers in Endocrinology·Leonid E FridlyandLouis H Philipson
Nov 29, 2017·Proceedings of the National Academy of Sciences of the United States of America·Menaka C ThounaojamManuela Bartoli
Oct 9, 2019·Molecular Psychiatry·Stefan R BornsteinRichard Straube
Mar 27, 2018·Clinical Cardiology·Ajay N SharmaGagan D Singh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Biomarkers for Diabetes

This feed focuses on the latest research on biomarkers used for monitoring disease progression in diabetes.

Related Papers

Cardiovascular & Hematological Disorders Drug Targets
Joanne Hsieh, Khosrow Adeli
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme
H E Harrison, T E Robinson
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD
E Mannucci, C M Rotella
© 2021 Meta ULC. All rights reserved